secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001493152-25-029363
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt
--------------------------------------------------------------------------------

- Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.
- R&D expenses surged to $237,501 from $48,500, driven by wages $161,875 and supplies $75,626.
- Cash remains $1; total assets $180,708; current liabilities $1,403,120 (including $1.31M due to parent BriaCell).
- Shareholders' deficit $1,390,648; accumulated deficit $1,425,163; going concern uncertainty noted as dependent on BriaCell funding.
- No auditor review performed; warrants liability $168,236 with Black-Scholes valuation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315225029363/0001493152-25-029363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315225029363/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-029363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer